Navigation Links
New study pinpoints biochemical mechanism underlying fibrosis following glaucoma surgery
Date:5/17/2013

Philadelphia, PA, May 17, 2013 The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial growth factor (VEGF) activates fibrosis, whereas VEGF inhibition results in reduced scar formation and better surgical results. In a series of studies using a rabbit model of glaucoma surgery, investigators have determined that VEGF probably exerts its effects through induction of transforming growth factor (TGF)-β1, which may open up a new target for therapies to improve glaucoma surgical outcomes. This study is published in the June 2013 issue of The American Journal of Pathology.

"The cytokine TGF-β1 is a key mediator of wound healing and is critically involved in postoperative scarring," says Chan Kee Park, MD, PhD, Department of Ophthalmology and Visual Science of Seoul St. Mary's Hospital and the College of Medicine of the Catholic University of Korea. "Our present study shows that VEGF induces TGF-β1 production, and inhibiting VEGF reduces TFG-β1 levels and decreases subconjunctival fibrosis after trabeculectomy." Trabeculectomy is the surgical process by which a filtering bleb is made under the conjunctival and subconjunctival space for the aqueous humor to be driven from the anterior eye chamber, lowering the pressure within the eye.

In this study of 32 white rabbits, some underwent trabeculectomy and others remained unoperated as controls. Immediately after surgery, some rabbits received intraocular injections of 0.2 ml of VEGF at doses ranging from 1 to 50 ng/mL, while others were injected with the VEGF inhibitor bevacizumab in the subconjunctival space.

One of the questions addressed by the researchers was whether VEGF triggers the transformation of fibroblasts to myofibroblasts in the subconjunctiva, since myofibroblasts play a significant role in fibrosis. Using immunohistochemical staining, the researchers found that trabeculectomy activated myoblast transformation as measured by levels of Smad-positive and Snail-positive cells in the conjunctiva and subconjunctiva. This effect increased after VEGF stimulation. Similarly, Western blot analysis of proteins showed increased levels of Smad, phosphorylated Smad, and Snail after surgery, which was intensified by VEGF and inhibited by bevacizumab.

"Our findings suggest that VEGF has potential effects on the TGF-1β/Smad/Snail pathway involved in myoblast transformation. Our study gives an experimental basis for the use of anti-VEGF agents in glaucoma surgery," says Dr. Park.


'/>"/>

Contact: David Sampson
ajpmedia@elsevier.com
215-239-3171
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. Study: Patient openness to research can depend on race and sex of study personnel
2. The Institute of Regenerative & Molecular Orthopedics Applauds Newly Released Study on Platelet-Rich Plasma
3. Study suggests new role for ECMO in treating patients with cardiac arrest and profound shock
4. Bel Marra Health Reports on a New Study Revealing a Natural Remedy for Hypertension, Insomnia, and Aging
5. Study Finds Overweight Young Males Have a Greater Risk of Not Surviving Until Age 55, Making Weight Loss Supplements Like Prescopodene Helpful With Increasing Longevity
6. New Study Reveals that Fitness Levels May Affect Attention Span, Making Weight Loss, Such as With Prescopodene, Helpful With Promoting Concentration
7. New study recommends using active videogaming (exergaming) to improve childrens health
8. Study: Brain makes call on which ear is used for cell phone
9. 2013 Is the Year of Mobility in Government: Study Shows Media Landscape Shifting in Government Sector
10. Heart Risks Last Beyond Hospital Discharge, Study Finds
11. High-Frequency Noise Boosts Math Skills in Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... ... disorder management, today announced it has secured $9 million in Series A funding ... investors. The investment will be used by Somnoware to further fulfill its mission ...
(Date:5/4/2016)... ... May 04, 2016 , ... Olshan ... commercial real estate proudly announced that its service-based charitable program, Olshan Outreach, successfully ... portfolio-wide will continue Olshan Properties’ annual philanthropic tradition in 2016 with the ‘Fight ...
(Date:5/4/2016)... Charles, LA (PRWEB) , ... May 04, 2016 , ... ... Charles, LA area has teamed up with Big Brothers Big Sisters of Southwest Louisiana ... now being accepted here . , Big Brothers Big Sisters of Southwest Louisiana ...
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. Assili, dentist in ... office. Wisdom tooth removal, a common dental procedure, is performed for many adolescents and ... erupted, resulting in risks of complications. By providing wisdom tooth removal surgery at their ...
(Date:5/4/2016)... ... May 04, 2016 , ... Natalie Jill ... local company MitoXcell in preparation of the launch of her new book: Natalie Jill’s ... is a nutritional guide designed to jump start a new healthy lifestyle featuring simple ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is ... a video of two patients who tell their personal story and encourage those at risk ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... May 3, 2016  Forté Elements, LLC (Forté) is excited to announce the launch ... address the nutritional needs of recovery for a variety of clinical conditions. Founded in ... Photo - http://photos.prnewswire.com/prnh/20160502/362548 Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/2/2016)... 2016  Deerfield announced today it led the ... Inc. Graybug Vision is an early stage pharmaceutical ... care for ocular diseases including wet age-related macular ... first developed at Johns Hopkins University and has ... Graybug Vision is developing ophthalmology products ...
Breaking Medicine Technology: